Global Leading Market Research Publisher QYResearch announces the release of its latest report “Polyglucose and Sodium Chloride Injection – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Polyglucose and Sodium Chloride Injection market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Polyglucose and Sodium Chloride Injection was estimated to be worth USD 25.7 million in 2024 and is forecast to reach a readjusted size of USD 41.1 million by 2031, growing at a CAGR of 5.7% during the forecast period from 2025 to 2031. Polyglucose and Sodium Chloride Injection is an aqueous solution containing glucose (dextrose) and sodium chloride, primarily used to replenish water, electrolytes, and energy in patients with fluid deficits. For hospital pharmacy directors, intensive care unit managers, and healthcare procurement executives, the core challenge is maintaining adequate inventory of intravenous (IV) fluids across multiple formulation types while managing storage costs, expiration dates, and supply chain reliability. The solution lies in understanding the distinct clinical indications for different glucose-electrolyte combinations and establishing contracts with reliable manufacturers that can provide consistent quality, competitive pricing, and timely delivery.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/4662315/polyglucose-and-sodium-chloride-injection
Product Definition and Clinical Pharmacology
Polyglucose and Sodium Chloride Injection is a sterile, non-pyrogenic aqueous solution combining two essential components: glucose (a monosaccharide that serves as an immediate energy source for cellular metabolism) and sodium chloride (an electrolyte critical for maintaining body fluid osmotic pressure, nerve impulse transmission, and muscle function). The injection is administered via intravenous infusion and is rapidly absorbed and utilized by the body to help restore physiological functions and stabilize the internal environment. The combination provides three simultaneous therapeutic benefits: fluid resuscitation (restoring circulating volume), energy provision (preventing or treating hypoglycemia), and electrolyte repletion (correcting sodium and chloride deficiencies). This makes the product particularly valuable in clinical scenarios where patients cannot take oral fluids or nutrition, such as post-operative recovery, severe gastroenteritis, burn injury, or critical illness.
The pharmaceutical formulation is essentially a variation of the widely used 5% dextrose in 0.9% normal saline (D5NS), though the specific concentration described—60g condensed glucose per 500ml (12% w/v) or 30g per 250ml (12% w/v)—represents a hypertonic glucose concentration higher than standard maintenance IV fluids. Such concentrated formulations are typically indicated for patients requiring caloric supplementation with limited fluid volume capacity, such as those with heart failure, renal impairment, or severe edema where fluid restriction is necessary. The hypertonic glucose solution draws fluid from the interstitial space into the vascular compartment temporarily, requiring careful monitoring of blood glucose and serum osmolality during infusion.
Segment Analysis by Dosage Form
The Polyglucose and Sodium Chloride Injection market is segmented by dosage form into two primary types. The first type is 500ml containing 60g condensed glucose and 4.25g sodium chloride. This represents a glucose concentration of 12% (60g/500ml = 0.12g/ml or 12% w/v) and a sodium chloride concentration of 0.85% (4.25g/500ml = 0.0085g/ml or 0.85% w/v), slightly hypotonic compared to normal saline (0.9%). The 500ml bag is the larger volume option, typically used for adult patients requiring more substantial fluid and caloric support, particularly in general medical-surgical wards, emergency departments, and post-operative recovery units. The second type is 250ml containing 30g condensed glucose and 2.125g sodium chloride, maintaining the same concentration ratios (12% glucose, 0.85% sodium chloride) in a smaller total volume. The 250ml bag is preferred for pediatric patients, elderly patients with reduced fluid tolerance, or as a vehicle for compatible IV medication administration where lower fluid volume is desired. Based on QYResearch’s market analysis, the 500ml segment currently holds a larger market share, accounting for approximately 55% of global unit volume, while the 250ml segment is growing at a slightly faster rate due to increasing use in ambulatory infusion centers and home healthcare settings where smaller bag sizes offer greater convenience and reduced waste.
End-User Segmentation and Application Analysis
By application, the market serves three primary end-user categories: Hospital, Clinic, and Other (including ambulatory surgical centers, home infusion services, emergency medical services, and long-term care facilities). Hospitals currently hold the largest market share, accounting for approximately 65% of global revenue, driven by high-volume usage in surgical suites, intensive care units, emergency departments, and general medical wards. Within hospitals, Polyglucose and Sodium Chloride Injection is stocked as a standard formulary item for fluid and electrolyte management. The product is indicated for patients with dehydration (from causes such as severe vomiting, diarrhea, or inadequate oral intake), hypoglycemia (low blood sugar, particularly in diabetic patients or those with malnutrition), or electrolyte disorders (hyponatremia or hypochloremia). A typical hospital user case from Q1 2026: a 350-bed tertiary hospital in eastern China reported using approximately 18,000 units of glucose-sodium chloride injection annually, with peak usage during winter respiratory illness season when hospitalized children with gastroenteritis required IV rehydration. Clinics—including urgent care centers and outpatient infusion clinics—represent the second-largest and fastest-growing segment. These settings treat less acutely ill patients who require IV fluids but do not meet admission criteria, such as those with mild to moderate dehydration from viral illness or hangover treatment. The “Other” segment includes home infusion services, where visiting nurses administer IV fluids to patients with chronic conditions requiring periodic rehydration, and emergency medical services (ambulances) where pre-hospital fluid resuscitation may be initiated.
Key Players and Competitive Landscape
The competitive landscape for Polyglucose and Sodium Chloride Injection features a concentrated group of Chinese pharmaceutical manufacturers with expertise in large-volume parenteral (LVP) production, good manufacturing practice compliance, and established hospital distribution networks. Key players identified in QYResearch’s market analysis include Peking University Pharmaceutical Co., Ltd., Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd., Chongqing Dikang Changjiang Pharmaceutical Co., Ltd., Zhejiang Guojing Pharmaceutical Co., Ltd., Sichuan Kelun Pharmaceutical Co., Ltd., Shijiazhuang Siyao Co., Ltd., Huiyinbi Group Jiangxi East Asia Pharmaceutical Co., Ltd., and Yichang Three Gorges Pharmaceutical Co., Ltd.. Sichuan Kelun Pharmaceutical Co., Ltd. maintains a leading market share, leveraging its position as one of China’s largest manufacturers of IV fluids and infusion products. According to Kelun’s 2025 annual report, the company operates multiple LVP production facilities with combined annual capacity exceeding 2 billion bottles/bags, serving both domestic and export markets. Shijiazhuang Siyao Co., Ltd. (CSPC Pharmaceutical Group) brings its established quality systems and hospital sales force to this product category. An exclusive industry observation from this analysis is the highly localized nature of the IV fluid market. Due to the weight and volume of finished products (glass bottles or plastic bags filled with liquid), transportation costs are significant, leading most hospitals to source from regional manufacturers within 500 km. This creates a fragmented market structure with regional leaders rather than a single national dominant player. Recent developments from the past six months (December 2025 to May 2026) include the China National Medical Products Administration’s (NMPA) publication of updated good manufacturing practice guidance for large-volume parenterals, including enhanced requirements for sterility testing, endotoxin limits, and particulate matter control. This regulatory update favors larger manufacturers with established quality systems and may accelerate consolidation among smaller producers.
Market Outlook and Strategic Implications (2025-2031)
Looking forward, the Polyglucose and Sodium Chloride Injection market is projected to sustain its 5.7% CAGR, reaching USD 41.1 million by 2031. This steady growth reflects the essential, non-discretionary nature of IV fluids in acute care medicine, balanced against pricing pressures from hospital procurement groups and the availability of alternative fluid formulations (e.g., lactated Ringer’s, Plasma-Lyte, and other balanced electrolyte solutions). For healthcare procurement executives, key considerations include establishing contracts with multiple regional manufacturers to ensure supply chain resilience (as demonstrated during fluid shortages in previous years), negotiating volume-based pricing, and implementing inventory management systems to minimize expiration-related waste. For investors, the segment offers stable, predictable demand with moderate growth, characteristic of essential hospital consumables markets. The complete QYResearch report includes detailed volume-based forecasts by dosage form, regional consumption patterns across Chinese provinces, and competitive benchmarking of the eight leading manufacturers, along with analysis of raw material cost trends (pharmaceutical-grade glucose and sodium chloride) and their impact on manufacturer margins.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
